Axsome Therapeutics (AXSM) — insider trading
Health Care · NASDAQ
Axsome Therapeutics (AXSM) has 52 reported SEC Form 4 insider transactions in our data, including 17 open-market sales among the most recent 52 (latest 2026-09-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Jacobson Mark L. | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-09-03 | Jacobson Mark L. | Officer (Chief Operating Officer) | Open-market sale | 10,000 | $208.65 | $2.09M | Form 4 |
| 2026-09-03 | Jacobson Mark L. | Officer (Chief Operating Officer) | Option exercise / conversion | 10,000 | $12.95 | $129.5K | Form 4 |
| 2026-08-06 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion (derivative) | 4,660 | — | $0 | Form 4 |
| 2026-08-06 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Open-market sale | 4,660 | $213.95 | $997.0K | Form 4 |
| 2026-08-06 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion | 4,660 | $4.95 | $23.1K | Form 4 |
| 2026-08-05 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion (derivative) | 45,004 | — | $0 | Form 4 |
| 2026-08-05 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Open-market sale | 45,004 | $212.01 | $9.54M | Form 4 |
| 2026-08-05 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion | 45,004 | $4.95 | $222.8K | Form 4 |
| 2026-07-01 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion (derivative) | 49,666 | — | $0 | Form 4 |
| 2026-07-01 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Open-market sale | 49,666 | $240.25 | $11.93M | Form 4 |
| 2026-07-01 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion | 49,666 | $4.95 | $245.8K | Form 4 |
| 2026-06-11 | JEFFS ROGER | Director | Open-market sale | 286 | $249.12 | $71.2K | Form 4 |
| 2026-06-10 | JEFFS ROGER | Director | Open-market sale | 286 | $246.18 | $70.4K | Form 4 |
| 2026-06-10 | Coleman Mark | Director | Open-market sale | 643 | $249.00 | $160.1K | Form 4 |
| 2026-06-10 | Mahony Susan | Director | Open-market sale | 300 | $246.18 | $73.9K | Form 4 |
| 2026-06-09 | Mahony Susan | Director | Open-market sale | 300 | $237.21 | $71.2K | Form 4 |
| 2026-06-09 | Pizzie Nick | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 33,000 | — | $0 | Form 4 |
| 2026-06-09 | Pizzie Nick | Officer (Chief Financial Officer) | Open-market sale | 33,000 | $240.09 | $7.92M | Form 4 |
| 2026-06-09 | Pizzie Nick | Officer (Chief Financial Officer) | Option exercise / conversion | 33,000 | $3.50 | $115.5K | Form 4 |
| 2026-06-09 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion (derivative) | 49,670 | — | $0 | Form 4 |
| 2026-06-09 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Open-market sale | 49,670 | $241.01 | $11.97M | Form 4 |
| 2026-06-09 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion | 49,670 | $4.95 | $245.9K | Form 4 |
| 2026-06-08 | Coleman Mark | Director | Option exercise / conversion (derivative) | 1,429 | — | $0 | Form 4 |
| 2026-06-08 | Coleman Mark | Director | Option exercise / conversion | 1,429 | — | — | Form 4 |
| 2026-06-08 | Mahony Susan | Director | Option exercise / conversion (derivative) | 1,429 | — | $0 | Form 4 |
| 2026-06-08 | Mahony Susan | Director | Option exercise / conversion | 1,429 | — | — | Form 4 |
| 2026-06-08 | Saad Mark E | Director | Option exercise / conversion (derivative) | 1,429 | — | $0 | Form 4 |
| 2026-06-08 | Saad Mark E | Director | Option exercise / conversion | 1,429 | — | — | Form 4 |
| 2026-06-08 | JEFFS ROGER | Director | Option exercise / conversion (derivative) | 1,429 | — | $0 | Form 4 |
| 2026-06-08 | JEFFS ROGER | Director | Option exercise / conversion | 1,429 | — | — | Form 4 |
| 2026-06-05 | JEFFS ROGER | Director | Grant / award / vesting (derivative) | 1,721 | — | $0 | Form 4 |
| 2026-06-05 | Saad Mark E | Director | Grant / award / vesting (derivative) | 1,721 | — | $0 | Form 4 |
| 2026-06-05 | Mahony Susan | Director | Grant / award / vesting (derivative) | 1,721 | — | $0 | Form 4 |
| 2026-06-05 | Coleman Mark | Director | Grant / award / vesting (derivative) | 1,721 | — | $0 | Form 4 |
| 2026-06-02 | Coleman Mark | Director | Open-market sale | 5,537 | $223.39 | $1.24M | Form 4 |
| 2026-06-01 | Coleman Mark | Director | Open-market sale | 6,000 | $230.30 | $1.38M | Form 4 |
| 2026-05-29 | Coleman Mark | Director | Open-market sale | 6,000 | $233.46 | $1.40M | Form 4 |
| 2026-05-05 | Jacobson Mark L. | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 233 | — | $0 | Form 4 |
| 2026-05-05 | Jacobson Mark L. | Officer (Chief Operating Officer) | Open-market sale | 233 | $228.18 | $53.2K | Form 4 |
| 2026-05-05 | Jacobson Mark L. | Officer (Chief Operating Officer) | Option exercise / conversion | 233 | $12.95 | $3.0K | Form 4 |
| 2026-05-04 | Jacobson Mark L. | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 4,517 | — | $0 | Form 4 |
| 2026-05-04 | Jacobson Mark L. | Officer (Chief Operating Officer) | Open-market sale | 4,517 | $227.94 | $1.03M | Form 4 |
| 2026-05-04 | Jacobson Mark L. | Officer (Chief Operating Officer) | Option exercise / conversion | 4,517 | $12.95 | $58.5K | Form 4 |
| 2026-04-22 | Maizel Ari | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-04-22 | Maizel Ari | Officer (Chief Commercial Officer) | Open-market sale | 7,500 | $182.42 | $1.37M | Form 4 |
| 2026-04-22 | Maizel Ari | Officer (Chief Commercial Officer) | Option exercise / conversion | 7,500 | $70.73 | $530.5K | Form 4 |
| 2026-04-21 | Murdock Hunter R. | Officer (General Counsel) | Grant / award / vesting (derivative) | 7,224 | — | $0 | Form 4 |
| 2026-04-21 | Pizzie Nick | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 8,188 | — | $0 | Form 4 |
| 2026-04-21 | Maizel Ari | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 7,224 | — | $0 | Form 4 |
| 2026-04-21 | TABUTEAU HERRIOT | Director, Officer (Chief Executive Officer), 10% owner | Grant / award / vesting (derivative) | 24,081 | — | $0 | Form 4 |
| 2026-04-21 | Jacobson Mark L. | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 8,669 | — | $0 | Form 4 |
Ask the chat about AXSM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Axsome Therapeutics (AXSM).
Last updated 2026-09-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.